This study investigates whether a specific type of radiation therapy, called stereotactic ablative body radiation (SABR), is safe and effective for treating early-stage squamous cell carcinoma of the lung. Squamous cell carcinoma is a kind of lung cancer that starts in the flat cells lining the lungs. The study aims to find out if patients can safely receive higher doses of radiation than what is currently standard.
Participants in this study will receive SABR, which involves targeted radiation treatment. The study will compare the effects of a higher dose of radiation to the standard dose to see if it better controls the cancer. The safety of these doses will also be evaluated throughout the study.
- Who can participate: Individuals with a confirmed diagnosis of squamous cell carcinoma of the lung can participate. Those who have previously received radiation therapy to the lung are not eligible.
- Study details: Participants will receive a type of radiation treatment called SABR. The study will involve comparing different doses of radiation to determine their safety and effectiveness.
How understandable was the trial content above?
Hard to understand
Easy to understand
